Crucell Discovers MAbs for Protection Against H5N1 Strains

Oct 09, 2007
By BioPharm International Editors

Crucell N.V. (Leiden, the Netherlands) has discovered a set of human monoclonal antibodies (MAbs) that work to neutralize and protect against H5N1.

The company has discovered total of 21 human MAbs that can neutralize the H5N1 virus of avian influenza, which currently presents a global threat. The most potent of the antibodies was shown to neutralize the broadest range of H5N1 strains that have emerged between 1997 and 2004. This antibody also has been shown to prevent influenza in preclinical models when given 24 hours before being challenged with a lethal dose of highly pathogenic H5N1 virus. When given three days after infection, it also was shown to prevent death and cure the disease.

Crucell release